Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Tsao, Nicole W.
Bansback, Nick J.
Shojania, Kam
and
Marra, Carlo A.
2012.
The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
Best Practice & Research Clinical Rheumatology,
Vol. 26,
Issue. 5,
p.
659.
Valor, Lara
and
de la Torre Ortega, Inmaculada
2012.
Should We Use Poor Prognosis Factors to Start Early Treatment in Patients With Rheumatoid Arthritis?.
Reumatología Clínica (English Edition),
Vol. 8,
Issue. 4,
p.
163.
Valor, Lara
and
de la Torre Ortega, Inmaculada
2012.
¿Debemos usar los factores de mal pronóstico para iniciar precozmente un tratamiento biológico en los pacientes con artritis reumatoide?.
Reumatología Clínica,
Vol. 8,
Issue. 4,
p.
163.
Scholz, Stefan
and
Mittendorf, Thomas
2014.
Modeling rheumatoid arthritis using different techniques - a review of model construction and results.
Health Economics Review,
Vol. 4,
Issue. 1,
Borrás-Blasco, Joaquín
Gracia-Pérez, Antonio
Rosique-Robles, J Dolores
Casterá, MD Elvira
and
Abad, F Javier
2014.
Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.
Expert Opinion on Biological Therapy,
Vol. 14,
Issue. 2,
p.
145.
Tosh, Jonathan
Stevenson, Matt
and
Akehurst, Ron
2014.
Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review.
Current Rheumatology Reports,
Vol. 16,
Issue. 10,
van Haalen, H. G. M.
Severens, J. L.
Tran-Duy, A.
and
Boonen, A.
2014.
How to Select the Right Cost-Effectiveness Model?.
PharmacoEconomics,
Vol. 32,
Issue. 5,
p.
429.
van Herwaarden, Noortje
den Broeder, Alfons A
Jacobs, Wilco
van der Maas, Aatke
Bijlsma, Johannes WJ
van Vollenhoven, Ronald F
and
van den Bemt, Bartholomeus JF
2014.
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Cochrane Database of Systematic Reviews,
Kobelt, Gisela
2014.
Treating to Target with Etanercept in Rheumatoid Arthritis: Cost-Effectiveness of Dose Reductions When Remission Is Achieved.
Value in Health,
Vol. 17,
Issue. 5,
p.
537.
Inciarte-Mundo, José
Hernández, M. Victoria
Rosario, Violeta
Ruiz-Esquide, Virginia
Cabrera-Villalba, Sonia
Ramírez, Julio
Cañete, Juan D.
and
Sanmartí, Raimon
2014.
Reduction of Biological Agent Dose in Rheumatic Diseases: Descriptive Analysis of 153 Patients in Clinical Practice Conditions.
Reumatología Clínica (English Edition),
Vol. 10,
Issue. 1,
p.
10.
Heather, Eleanor M.
Payne, Katherine
Harrison, Mark
and
Symmons, Deborah P. M.
2014.
Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models.
PharmacoEconomics,
Vol. 32,
Issue. 2,
p.
109.
Inciarte-Mundo, José
Hernández, M. Victoria
Rosario, Violeta
Ruiz-Esquide, Virginia
Cabrera-Villalba, Sonia
Ramírez, Julio
Cañete, Juan D.
and
Sanmartí, Raimon
2014.
Reducción de dosis de terapias biológicas en enfermedades reumáticas: análisis descriptivo de 153 pacientes en condiciones de práctica clínica.
Reumatología Clínica,
Vol. 10,
Issue. 1,
p.
10.
Krol, Marieke
Papenburg, Jocé
and
van Exel, Job
2015.
Does Including Informal Care in Economic Evaluations Matter? A Systematic Review of Inclusion and Impact of Informal Care in Cost-Effectiveness Studies.
PharmacoEconomics,
Vol. 33,
Issue. 2,
p.
123.
Berto, Patrizia
Adami, Silvano
Botsios, Costantino
Fantelli, Valentina
Grion, Anna Maria
Ometto, Francesca
Punzi, Leonardo
Roni, Chiara
and
Scroccaro, Giovanna
2015.
Real World Data use and Applications in the Integrated Management of Rheumatic Disease.
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish,
Vol. 2,
Issue. 3,
p.
GRHTA.5000212.
Stephens, Stephanie
Botteman, Marc F
Cifaldi, Mary A
and
van Hout, Ben A
2015.
Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
BMJ Open,
Vol. 5,
Issue. 6,
p.
e006560.
Joensuu, Jaana T.
Huoponen, Saara
Aaltonen, Kalle J.
Konttinen, Yrjö T.
Nordström, Dan
Blom, Marja
and
Coles, Jonathan A
2015.
The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review.
PLOS ONE,
Vol. 10,
Issue. 3,
p.
e0119683.
Ganz, Michael L.
Hansen, Brian Bekker
Valencia, Xavier
and
Strandberg-Larsen, Martin
2015.
Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis.
Journal of Medical Economics,
Vol. 18,
Issue. 5,
p.
366.
Krol, Marieke
and
Brouwer, Werner
2015.
Unpaid work in health economic evaluations.
Social Science & Medicine,
Vol. 144,
Issue. ,
p.
127.
Stevenson, Matt
Archer, Rachel
Tosh, Jon
Simpson, Emma
Everson-Hock, Emma
Stevens, John
Hernandez-Alava, Monica
Paisley, Suzy
Dickinson, Kath
Scott, David
Young, Adam
and
Wailoo, Allan
2016.
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Health Technology Assessment,
Vol. 20,
Issue. 35,
p.
1.
Cantini, Fabrizio
Niccoli, Laura
Nannini, Carlotta
Cassarà, Emanuele
Kaloudi, Olga
Giulio Favalli, Ennio
Becciolini, Andrea
Biggioggero, Martina
Benucci, Maurizio
Li Gobbi, Francesca
Grossi, Valentina
Infantino, Maria
Meacci, Francesca
Manfredi, Mariangela
Guiducci, Serena
Bellando-Randone, Silvia
Matucci-Cerinic, Marco
Foti, Rosario
Di Gangi, Marcella
Mosca, Marta
Tani, Chiara
Palmieri, Fabrizio
and
Goletti, Delia
2016.
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Seminars in Arthritis and Rheumatism,
Vol. 45,
Issue. 5,
p.
519.